AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer

Abstract Background Immune checkpoint inhibitors (ICIs) reported remarkable achievements in several solid tumours. However, in metastatic colorectal cancer (mCRC) promising results are limited to patients with deficient mismatch repair/microsatellite instability-high (dMMR/MSI-high) tumours due to t...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Carlotta Antoniotti, Beatrice Borelli, Daniele Rossini, Filippo Pietrantonio, Federica Morano, Lisa Salvatore, Sara Lonardi, Federica Marmorino, Stefano Tamberi, Salvatore Corallo, Giampaolo Tortora, Francesca Bergamo, Di Stefano Brunella, Alessandra Boccaccino, Elisa Grassi, Patrizia Racca, Emiliano Tamburini, Giuseppe Aprile, Roberto Moretto, Luca Boni, Alfredo Falcone, Chiara Cremolini
Формат: Artigo
Язык:Inglês
Опубликовано: BMC 2020-07-01
Серии:BMC Cancer
Предметы:
FOLFOXIRI
Metastatic colorectal cancer
Immunotherapy
Immune checkpoint inhibitors
Atezolizumab
Chemotherapy
Online-ссылка:http://link.springer.com/article/10.1186/s12885-020-07169-6
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы